Added to YB: 2026-03-09
Pitch date: 2026-03-05
RCKT [bearish]
Rocket Pharmaceuticals, Inc.
-8.13%
current return
Author Info
No bio for this author
Company Info
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Market Cap
$523.3M
Pitch Price
$4.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.66
P/E
-2.40
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
I’m officially short $RCKT.
RCKT (short): Fatal flaw in SAP uses 39% survival-to-24mo benchmark vs median patient age 42.3mo at infusion—survivorship bias. Protocol v3.0 switched endpoint to 1yr for older kids but kept infant mortality hurdle. 100% survival headline is statistical artifact from left truncation. FDA warned on immortal-time bias in external controls; Prasad likely issues CRL March 28.
Read full article (2 min)